• Explore /
  • Poster
  • / A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.

Abstract Video & Slides Poster

Authors

null

Laura Quan Man Chow

University of Washington, Seattle, WA

Laura Quan Man Chow , Justin F. Gainor , Nehal J. Lakhani , Keun Wook Lee , Hyun Cheol Chung , Jeeyun Lee , Patricia LoRusso , Yung-Jue Bang , F. Stephen Hodi , Rafael Santana-Davila , Philip Fanning , Pierre Squifflet , Feng Jin , Hong Wan , Tracy Kuo , Jaume Pons , Sophia Randolph , Wells A. Messersmith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03013218

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3056)

DOI

10.1200/JCO.2020.38.15_suppl.3056

Abstract #

3056

Poster Bd #

120

Abstract Disclosures

Similar Posters

First Author: Laura Quan Man Chow

First Author: Daniel V.T. Catenacci

First Author: Timothy Jay Price

First Author: Elena Garralda